- Home
- AGCC vs RGNX Comparison
AGCC vs RGNX Comparison
Compare AGCC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGCC | RGNX |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | Taiwan | United States |
| Employees | 23 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.8M | 418.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AGCC | RGNX |
|---|---|---|
| Price | $18.65 | $10.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 95.7K | ★ 577.6K |
| Earning Date | 05-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | $168.97 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $4.23 | $7.35 |
| 52 Week High | $25.73 | $16.19 |
Technical Indicators
Market Signals| Indicator | AGCC | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 66.86 |
| Support Level | $13.30 | $7.76 |
| Resistance Level | $25.35 | $12.05 |
| Average True Range (ATR) | 3.08 | 0.57 |
| MACD | -0.18 | 0.17 |
| Stochastic Oscillator | 43.23 | 85.95 |
Price Performance
Historical ComparisonAbout AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares
Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.